Topic: Retinal Disease

Interventions of Interest ICER assessed the comparative clinical effectiveness and value of sonpiretigene isteparvovec (Nanoscope Therapeautics) for the treatment of advanced retinitis pigmentosa. An independent appraisal committee voted that the current evidence is adequate to demonstrate a net health benefit of sonpiretigene isteparvovec compared to usual care. Final Documents For questions please contact [email protected]. View […]

ICER developed a report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Luxturna®, Spark Therapeutics), a potentially one-time gene therapy for vision loss associated with biallelic RPE65-mediated retinal disease. Voretigene neparvovec is the first gene therapy to be approved by the US Food and Drug Administration (FDA). The appraisal committee vote revealed differences […]